Cargando…
Dual Antiplatelet Therapy in Coronary Artery Disease: Comparison Between ACC/AHA 2016 and ESC 2017 Guidelines
Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but there remains uncertainty as to the optimal approach for balancing an individual’s risk of atherothrombotic events versus their risk of bleeding complications. A myriad of clinical trials have investi...
Autor principal: | Floyd, Christopher N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066853/ https://www.ncbi.nlm.nih.gov/pubmed/32180836 http://dx.doi.org/10.15420/ecr.2019.09 |
Ejemplares similares
-
Comparison of ESC and ACC/AHA guidelines for myocardial revascularization
por: Stirrup, Jim, et al.
Publicado: (2017) -
ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison
por: Behnoush, Amir Hossein, et al.
Publicado: (2022) -
Impact of 2018 ESC/ESH and 2017 ACC/AHA Hypertension Guidelines: Difference in Prevalence of White-Coat and Masked Hypertension
por: Kim, Byong-Kyu, et al.
Publicado: (2020) -
The potential for overdiagnosis and underdiagnosis because of blood pressure variability: a comparison of the 2017 ACC/AHA, 2018 ESC/ESH and 2019 NICE hypertension guidelines
por: Bell, Katy, et al.
Publicado: (2021) -
Incident cerebral microbleeds and hypertension defined by the 2017 ACC/AHA Guidelines
por: Xia, Yiwei, et al.
Publicado: (2021)